MorphoSys AG

General Information
Business:

(Note: “We are offering 8,300,000 ADSs, assuming a public offering price of $24.12 per ADS based on the Xetra closing price of our ordinary shares on the Frankfurt Stock Exchange on April 6, 2018, of 78.85 and assuming an exchange rate of $1.2234 per euro. Our shares have traded on the Frankfort Stock Exchange since 2013.”)

We are a late-stage biopharmaceutical company devoted to the development of innovative and differentiated therapies for patients suffering from serious diseases. Based on our proprietary technology platforms and leadership in the field of therapeutic antibody discovery, generation and engineering, we, together with our partners, have participated in the development of more than 100 therapeutic product candidates. Our broad pipeline spans two business segments: Proprietary Development, in which we invest in and develop product candidates, and Partnered Discovery, in which we generate product candidates for our partners in the pharmaceutical and biotechnology industries against targets identified by our partners.

 

Industry: PHARMACEUTICAL PREPARATIONS
Employees: 326
Founded: 1992
Contact Information
Address Semmelweisstrasse 7, 82152 Planegg, Germany
Phone Number +49 89-89927-0
Web Address http://www.morphosys.com
View Prospectus: MorphoSys AG
Financial Information
Market Cap
Revenues $80.3 mil (last 12 months)
Net Income $-83.9 mil (last 12 months)
IPO Profile
Symbol MOR
Exchange NASDAQ
Shares (millions): 8.3
Price range $25.04 - $25.04
Est. $ Volume $207.8 mil
Manager / Joint Managers Goldman Sachs/ J.P. Morgan/ Leerink Partners
CO-Managers Berenberg Capital Markets/ JMP Securities
Expected To Trade: 4/19/2018
Status:
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change